Alejandro Carvallo
Nephrology · Zephyrhills, FLNPI 1053416412
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.9% of the total across 106 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 24.6% of the total. Reporting peaked in 2019 at $1,228 and has fallen 98.3% since, to $21 in 2025.
Across 106 payments — averaging $21.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$563
- Amgen$332
- AstraZeneca$213
- Daiichi Sankyo Inc.$190
- Akebia Therapeutics Inc$177
- OPKO Pharmaceuticals, LLC$159
- plus $650 from 15 others
What the payments were for
- Food & beverage$2,12193%
- Education$1637%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 22 | $563 |
| Amgen(2 entities) | 18 | $332 |
| AstraZeneca(2 entities) | 13 | $213 |
| Daiichi Sankyo Inc. | 8 | $190 |
| Akebia Therapeutics Inc | 7 | $177 |
| OPKO Pharmaceuticals, LLC | 8 | $159 |
| Mallinckrodt Enterprises LLC | 3 | $150 |
| Vifor Pharma, Inc. | 7 | $109 |
| Bayer | 4 | $74 |
| Baxter Healthcare | 3 | $66 |
| GSK | 2 | $41 |
| Mallinckrodt Hospital Products Inc. | 1 | $28 |
| AbbVie | 1 | $28 |
| Fresenius USA Marketing, Inc. | 2 | $27 |
| Aurinia Pharma U.S., Inc. | 1 | $24 |
| Bard Peripheral Vascular, Inc. | 1 | $21 |
| Boston Scientific | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Ultragenyx Pharmaceutical Inc. | 1 | $11 |
How this compares
$2,284 in reported general payments places this provider in the 60th percentile of 756 nephrology providers in Florida.
Other nephrology in Zephyrhills
- Arvind MadanOrlando$943K
- John CopleyWeston$934K
- Jorge LarranagaKissimmee$825K
- Carlos BejarFort Lauderdale$530K
- Wayne KotzkerFort Lauderdale$472K
- Jason RothschildTemple Terrace$413K
- Daniel PatelDaytona Beach$227K
- Rafael Baez BonillaFort Lauderdale$175K
- Gabriel ContrerasMiami$133K
- Fouad ChebibJacksonville$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.